$ 177.47 <%= Resources.Global.txtDown %>
Updated 17/04/2019
Change % -2.74% Stock price decreasing
Change -5.00 Stock price decreasing
Volume 5,866,904
High $ 183.49
Low $ 176.85
Open $ 183.49
ISIN
Prev close $ 182.47
# of shares 615.95M
Market cap 109,313M USD
Intraday

Market closed
Amgen Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  177.47 -7.3% Stock price decreasing -7.5% Stock price decreasing -13.0% Stock price decreasing -12.1% Stock price decreasing 3.4% Stock price increasing
Powered by TradingView

News about Amgen Inc

  • English
  • Regulatory news

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Abbott Laboratories 73.92 -5.2% Stock price decreasing -7.7% Stock price decreasing 3.5% Stock price increasing 9.4% Stock price increasing 24.9% Stock price increasing 2.2% Stock price increasing
 
Bristol-Myers Squibb Company 45.52 -0.1% Stock price decreasing -7.0% Stock price decreasing -9.2% Stock price decreasing -16.2% Stock price decreasing -11.0% Stock price decreasing -12.4% Stock price decreasing
 
Johnson & Johnson 137.52 1.1% Stock price increasing -0.4% Stock price decreasing 5.2% Stock price increasing -1.1% Stock price decreasing 8.6% Stock price increasing 6.6% Stock price increasing
 
Eli Lilly and Company 115.20 -6.4% Stock price decreasing -10.2% Stock price decreasing -1.2% Stock price decreasing 2.9% Stock price increasing 45.7% Stock price increasing -0.4% Stock price decreasing
 
Merck & Company Inc (new) 73.19 -7.9% Stock price decreasing -11.8% Stock price decreasing -3.5% Stock price decreasing 1.2% Stock price increasing 24.4% Stock price increasing -4.2% Stock price decreasing
 
Pfizer Inc 39.38 -5.6% Stock price decreasing -7.0% Stock price decreasing -7.4% Stock price decreasing -11.5% Stock price decreasing 7.5% Stock price increasing -9.8% Stock price decreasing
 
Merck Kgaa O.N. 93.78 -3.5% Stock price decreasing -6.5% Stock price decreasing 4.1% Stock price increasing 0.1% Stock price increasing 14.3% Stock price increasing 4.2% Stock price increasing
 
Novartis NAM SF 0,50 67.82 -5.2% Stock price decreasing -17.9% Stock price decreasing -12.5% Stock price decreasing -10.7% Stock price decreasing 6.6% Stock price increasing -8.8% Stock price decreasing
 
Roche Hldg AG GEN 233.05 -1.3% Stock price decreasing -1.6% Stock price decreasing 3.2% Stock price increasing 10.3% Stock price increasing 28.9% Stock price increasing 8.1% Stock price increasing
 
Glaxosmithkline PLC ORD 25P 1,524.40 -1.7% Stock price decreasing -2.7% Stock price decreasing 2.2% Stock price increasing -2.1% Stock price decreasing 6.6% Stock price increasing 2.2% Stock price increasing
 
Takeda PHARM.CO.LTD. 32.00 -4.9% Stock price decreasing -14.7% Stock price decreasing -11.0% Stock price decreasing -10.2% Stock price decreasing -13.1% Stock price decreasing 10.6% Stock price increasing
 
Sanofi 72.87 -3.4% Stock price decreasing -8.6% Stock price decreasing -0.3% Stock price decreasing -6.3% Stock price decreasing 11.6% Stock price increasing -3.7% Stock price decreasing
 
Biogen Inc 226.39 -3.5% Stock price decreasing -0.2% Stock price decreasing -32.9% Stock price decreasing -29.3% Stock price decreasing -13.9% Stock price decreasing -24.8% Stock price decreasing
 
Bayer AG NA O.N. 61.16 -0.4% Stock price decreasing -0.2% Stock price decreasing -7.3% Stock price decreasing -21.2% Stock price decreasing -38.2% Stock price decreasing 1.0% Stock price increasing
 
Teva Pharmaceutical Industries.. 14.36 -0.1% Stock price decreasing -15.9% Stock price decreasing -23.7% Stock price decreasing -33.0% Stock price decreasing -19.4% Stock price decreasing -6.9% Stock price decreasing

Company profile

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Peers

Instruments Last Change  
Abbott Labor.. 73.92 1.4% Stock price increasing
Bristol-Myer.. 45.52 -0.6% Stock price decreasing
Johnson & Jo.. 137.52 -0.7% Stock price decreasing
Eli Lilly an.. 115.20 -1.1% Stock price decreasing
Merck & Comp.. 73.19 -1.0% Stock price decreasing
Pfizer Inc 39.38 -1.3% Stock price decreasing
Merck Kgaa O.. 93.78 -1.2% Stock price decreasing
Novartis NAM.. 67.82 -1.8% Stock price decreasing
Roche Hldg A.. 233.05 -0.6% Stock price decreasing
Glaxosmithkl.. 1,524.40 -1.1% Stock price decreasing
Takeda PHARM.. 32.00 -3.1% Stock price decreasing
100,33,20,83,0,0,0,33,44,44
Sanofi 72.87 -0.3% Stock price decreasing
Biogen Inc 226.39 -0.3% Stock price decreasing
Bayer AG NA .. 61.16 -0.6% Stock price decreasing
Teva Pharmac.. 14.36 1.0% Stock price increasing

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 April 2019 09:59:19
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190410.2 - EUROWEB6 - 2019-04-21 10:59:19 - 2019-04-21 09:59:19 - 1000 - Website: OKAY